Varsha Gandhi, PhD, on Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Dec

Today In Oncology

Varsha Gandhi, PhD, on Ibrutinib

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma